| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7037529 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
| US6589552 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6074670 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US7041319 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailabilty |
Jan, 2018
(6 years ago) | |
| US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6375986 | ABBVIE | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(1 year, 2 months ago) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(1 year, 2 months ago) | |
Tricor is owned by Abbvie.
Tricor contains Fenofibrate.
Tricor has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Tricor are:
- US7037529
- US6652881
- US6589552
- US6074670
- US7041319
- US6277405
- US6375986
- US7320802
- US7276249
- US6277405
- US6652881
Tricor was authorised for market use on 05 November, 2004.
Tricor is available in tablet;oral dosage forms.
Tricor can be used as adjunctive therapy to diet in adults to reduce ldl-c, total-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v), adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).
The generics of Tricor are possible to be released after 21 February, 2023.
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, total-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to t...
Dosage: TABLET;ORAL
TRICOR family patents
